Information Provided By:
Fly News Breaks for November 25, 2019
CRSP
Nov 25, 2019 | 07:44 EDT
Oppenheimer analyst Silvan Tuerkcan raised his price target for Crispr Therapeutics to $80 from $65 after the company announced CTX001 results last week, saying the results overall surpassed his expectations, but patient number is only two. While this data is very preliminary, Tuerkcan tells investors in a research note that he believes it warrants read-across to other ex-vivo projects based on Crispr's ability to execute in manufacturing, cell transplants. He maintains an Outperform rating on the shares.
News For CRSP From the Last 2 Days
CRSP
CRSP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.